Pfizer Reports Encouraging Overall Survival Results in Phase 3 Study of ADCETRIS® Treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma
Pfizer Inc. (NYSE: PFE) has disclosed promising findings from a Phase 3 clinical trial investigating the efficacy of the antibody-drug conjugate ADCETRIS® (brentuximab vedotin) in conjunction with lenalidomide and rituximab for treating patients afflicted with relapsed/refractory diffuse large B-cell lymphoma…